A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormone for idiopathic short stature

Andrea K. Goldyn, Zeina Nabhan, Erica Eugster

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Short stature is a common reason for referral to the pediatric endocrine clinic. In 2003, the US Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of children with idiopathic short stature (ISS). Objective: To explore if this indication changed referrals for short stature (SS). Design/Methods: A retrospective chart review of children seen for SS in the pediatric endocrine clinic between July 1998 and June 1999 (interval one, n=138) and July 2005 - June 2006 (interval two, n=268) was performed. Variables collected included age, gender, height (h), and parental heights. Results: Average height standard deviation score (HT-SDS) was - 2.11±0.9 in interval one and - 2.14±0.83 in interval two (p=ns). No differences in age, gender distribution, relationship between child and parental heights, the proportion of subjects started on GH for ISS or in the HT-SDS of those treated between the two intervals were identified. Nearly half of all children referred in each interval did not meet the technical criteria for short stature. Conclusions: No differences in referral patterns for SS in our area following FDA approval of GH for ISS were identified. Although referrals appear unchanged, additional investigation of GH prescribing patterns before and after this new indication is needed. Continued education of primary care physicians and the general public regarding the definition of SS and the eligibility for GH therapy should be pursued.

Original languageEnglish
Pages (from-to)89-91
Number of pages3
JournalJournal of Pediatric Endocrinology and Metabolism
Volume24
Issue number1-2
DOIs
StatePublished - Mar 2011

Fingerprint

Drug Approval
United States Food and Drug Administration
Growth Hormone
Referral and Consultation
Pediatrics
Age Distribution
Primary Care Physicians
Education
Therapeutics

Keywords

  • Growth hormone
  • Idiopathic short stature

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{39550ac0a6d34a98840c34a0d562a801,
title = "A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormone for idiopathic short stature",
abstract = "Background: Short stature is a common reason for referral to the pediatric endocrine clinic. In 2003, the US Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of children with idiopathic short stature (ISS). Objective: To explore if this indication changed referrals for short stature (SS). Design/Methods: A retrospective chart review of children seen for SS in the pediatric endocrine clinic between July 1998 and June 1999 (interval one, n=138) and July 2005 - June 2006 (interval two, n=268) was performed. Variables collected included age, gender, height (h), and parental heights. Results: Average height standard deviation score (HT-SDS) was - 2.11±0.9 in interval one and - 2.14±0.83 in interval two (p=ns). No differences in age, gender distribution, relationship between child and parental heights, the proportion of subjects started on GH for ISS or in the HT-SDS of those treated between the two intervals were identified. Nearly half of all children referred in each interval did not meet the technical criteria for short stature. Conclusions: No differences in referral patterns for SS in our area following FDA approval of GH for ISS were identified. Although referrals appear unchanged, additional investigation of GH prescribing patterns before and after this new indication is needed. Continued education of primary care physicians and the general public regarding the definition of SS and the eligibility for GH therapy should be pursued.",
keywords = "Growth hormone, Idiopathic short stature",
author = "Goldyn, {Andrea K.} and Zeina Nabhan and Erica Eugster",
year = "2011",
month = "3",
doi = "10.1515/JPEM.2011.120",
language = "English",
volume = "24",
pages = "89--91",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1-2",

}

TY - JOUR

T1 - A comparison of referral patterns to the pediatric endocrine clinic before and after FDA approval of growth hormone for idiopathic short stature

AU - Goldyn, Andrea K.

AU - Nabhan, Zeina

AU - Eugster, Erica

PY - 2011/3

Y1 - 2011/3

N2 - Background: Short stature is a common reason for referral to the pediatric endocrine clinic. In 2003, the US Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of children with idiopathic short stature (ISS). Objective: To explore if this indication changed referrals for short stature (SS). Design/Methods: A retrospective chart review of children seen for SS in the pediatric endocrine clinic between July 1998 and June 1999 (interval one, n=138) and July 2005 - June 2006 (interval two, n=268) was performed. Variables collected included age, gender, height (h), and parental heights. Results: Average height standard deviation score (HT-SDS) was - 2.11±0.9 in interval one and - 2.14±0.83 in interval two (p=ns). No differences in age, gender distribution, relationship between child and parental heights, the proportion of subjects started on GH for ISS or in the HT-SDS of those treated between the two intervals were identified. Nearly half of all children referred in each interval did not meet the technical criteria for short stature. Conclusions: No differences in referral patterns for SS in our area following FDA approval of GH for ISS were identified. Although referrals appear unchanged, additional investigation of GH prescribing patterns before and after this new indication is needed. Continued education of primary care physicians and the general public regarding the definition of SS and the eligibility for GH therapy should be pursued.

AB - Background: Short stature is a common reason for referral to the pediatric endocrine clinic. In 2003, the US Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the treatment of children with idiopathic short stature (ISS). Objective: To explore if this indication changed referrals for short stature (SS). Design/Methods: A retrospective chart review of children seen for SS in the pediatric endocrine clinic between July 1998 and June 1999 (interval one, n=138) and July 2005 - June 2006 (interval two, n=268) was performed. Variables collected included age, gender, height (h), and parental heights. Results: Average height standard deviation score (HT-SDS) was - 2.11±0.9 in interval one and - 2.14±0.83 in interval two (p=ns). No differences in age, gender distribution, relationship between child and parental heights, the proportion of subjects started on GH for ISS or in the HT-SDS of those treated between the two intervals were identified. Nearly half of all children referred in each interval did not meet the technical criteria for short stature. Conclusions: No differences in referral patterns for SS in our area following FDA approval of GH for ISS were identified. Although referrals appear unchanged, additional investigation of GH prescribing patterns before and after this new indication is needed. Continued education of primary care physicians and the general public regarding the definition of SS and the eligibility for GH therapy should be pursued.

KW - Growth hormone

KW - Idiopathic short stature

UR - http://www.scopus.com/inward/record.url?scp=79955499952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955499952&partnerID=8YFLogxK

U2 - 10.1515/JPEM.2011.120

DO - 10.1515/JPEM.2011.120

M3 - Article

C2 - 21528823

AN - SCOPUS:79955499952

VL - 24

SP - 89

EP - 91

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1-2

ER -